Potentials for dual RAAS blockade in the correction of endothelial dysfunction in hypertensive patients: comparative study
- Autores: Bagriy A.E1, Mikhailichenko E.S2, Kardashevskaya L.I1, Shchukina E.V1
-
Afiliações:
- M. Gorky Donetsk National Medical University
- LLC Formula Zdorovya
- Edição: Volume 26, Nº 9 (2019)
- Páginas: 73-76
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312319
- DOI: https://doi.org/10.18565/pharmateca.2019.9.73-76
- ID: 312319
Citar
Texto integral
![Acesso aberto](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Resumo
Background. The efficacy and safety of mineralocorticoid receptor antagonists (MRA) in arterial hypertension (AH) remain debatable. The effect of the dual renin-angiotensin-aldosterone system (RAAS) blockade with the use of the angiotensin II receptor antagonist and MRA on endothelial function in hypertensive patients requires investigation. Objective: Evaluation of the effect of combination therapy with valsartan and spironolactone on endothelial function in hypertensive patients. Methods. Sixty patients with stage 2 arterial hypertension were divided into 2 groups: group 1 received valsartan, group 2 - valsartan in combination with spironolactone. As appropriate, hydrochlorothiazide and/or amlodipine were added to therapy. The follow-up duration was 12 months. Before and at the end of the study, all patients underwent 24-hour blood pressure (BP) monitoring and reactive hyperemia test. Results. Target blood pressure levels were achieved in all cases. The degree of BP reduction and favorable effects on its daily profile were more pronounced in the group 2 (p<0.05). In both groups, a significant improvement in vascular reactivity was observed: in the group 1, against the background of reactive hyperemia, there was an increase in the diameter of the brachial artery by 9.3±3.89%, in the group 2 - by 17.68±5.89% (p<0.05). Conclusion. Combined therapy with valsartan and spironolactone was well-tolerated and has demonstrated a significant antihypertensive effect. The use of valsartan in combination with spironolactone was associated with a more pronounced improvement in endothelial function, according to the reactive hyperemia test.
Palavras-chave
Texto integral
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Sobre autores
A. Bagriy
M. Gorky Donetsk National Medical University
E. Mikhailichenko
LLC Formula Zdorovya
Email: klassiki@inbox.ru
Cardiologist
L. Kardashevskaya
M. Gorky Donetsk National Medical University
E. Shchukina
M. Gorky Donetsk National Medical University
Bibliografia
- Афонасьева Т.М. Эндотелиальная дисфункция. Возможности ранней диагностики. Здоровье и образование в XXI веке. 2016;18(11):101-4.
- Васина Л.В., Петрищев Н.Н., Власов Т.Д. Эндотелиальная дисфункция и ее основные маркеры. Регионарное кровообращение и микроциркуляция. 2017;16(1):4-15.
- Шилов А.В., Мнихович М.В., Калинин РЕ. и др. Morphological changes in the vascular wall during endothelial dysfunction. Журнал анатомии и гистопатологии 2017;6(2):115-21.
- Шабров А.В., Апресян А.Г., Добкес А.Л. и др. Современные методы оценки эндотелиальной дисфункции и возможности их применения в практической медицине. Рациональная фармакотерапия в кардиологии. 2016;12(6):733-42.
- Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. D0I:10.1093/eurheartj/ehy339.
- Luther J.M. Aldosterone in vascular and metabolic dysfunction. Curr Opin Nephrol Hypertens. 2016;25(1):16-21. DOI:http://dx.doi. org/10.1097/MNH.0000000000000189
- Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am Coll Cardiol. 2002;39(2):257-65. Do: 10.1016/S0735-1097(01)01746-6
- Weinberger M.H., Roniker B., Krause S.L., Weiss R.J. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J. Hypertens. 2002;15(8):709-16. Dor. 10.1016/S0895-7061(02)02957-6.
- Dahal K, Kunwar S., Rijal J, et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomised and non-randomised studies. Am J Hypertens. 2015;28(11):1376-85.
- Williams B., MacDonald T.M., Morant S., et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-68.
- Liu L., Xu B., Ju Y. Addition of spironolactone in patients with resistant hypertension: a meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2017;39:257-63. Doi: http://dx.doi.org/10.1080/ 10641963.2016.1246564
- Lyngs0 K.S., Assersen K., Dalgaard E.G., et al. Does Aldosterone Play a Significant Role for Regulation of Vascular Tone? J. Cardiovasc Pharmacol. 2015;68(1):1-10. DOI: http://dx.doi.org/10.1097/ FJC.0000000000000345
- Sica D.A. Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure. Methodist DeBakey Cardiovasc J. 2015;11(4):235-39. Doi: http://dx.doi.org/10.14797/mdcj-11-4-235
Arquivos suplementares
![](/img/style/loading.gif)